Drug intelligence / Profile preview

DS-200

Development stage: Preclinical
Lead developer: Eton Pharmaceuticals
Administration: Intravenous

Overview

DS-200 is an injectable hospital-use product candidate developed by Eton Pharmaceuticals. Its active ingredient has previously been supplied in the U.S. market as an unapproved drug product. DS-200 received FDA Fast Track designation and is intended to address serious conditions and unmet medical needs. Its precise active ingredient and mechanism of action are not specified in available public sources, but its status as a hospital-use injectable suggests it is intended for acute care settings.[3]

Brand names: DS-200DS200DS 200

Beyond the preview

Go deeper on DS-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DS-200.

Explore the full profile